Novartis Extends Fill/Finish Support For Pfizer/BioNTech COVID-19 Vaccines

by Vandana Singh, Benzinga Editor
October 21, 2021 7:02 AM | 1 min read |
  • Novartis AG NVS has agreed to expand its fill-and-finish support for Pfizer Inc PFE / BioNTech SE BNTX COVID-19 vaccine.
  • Novartis will use its sterile manufacturing facilities at its Novartis Technical Operations site in Ljubljana, Slovenia, to fill at least 24 million doses in 2022.
  • Novartis plans to take bulk mRNA active ingredient from BioNTech and fill them into vials under sterile conditions for shipment back to BioNTech for distribution.
  • This new agreement follows an earlier deal to fill and finish more than 50 million doses in 2021 at the Novartis Stein site in Switzerland.
  • Related: BioNTech Starts Production At New Germany Plant In Boost For COVID-19 Shots.
  • Price Action: NVS shares traded higher by 0.31% at $84.73 premarket on the last check Thursday.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: BiotechNewsHealth CareContractsGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!